NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Innodem Neurosciences

Innodem Neurosciences

Private
MontrealHealthcare & Life Scienceshttps://innodemneurosciences.com/

Last Round

Series A

Jan 19, 2021

Total Funding Raised

$6M

Company Overview

Innodem Neurosciences is a digital health and AI company that develops eye-tracking technology for the assessment and monitoring of neurodegenerative and mental diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Healthcare Analytics, Clinical Trials, Computer Vision

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

eye-trackingdigital biomarkerneurodegenerative diseaseAI diagnosticsoculomotor screeningmedical AIdigital healthmedtechtablet-based diagnosticsclinical decision supportgaze mappingremote monitoringclinical trial softwarecomputer visionSaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innodem Neurosciences Comparables

Compare Innodem Neurosciences with similar companies based on industry and business-model similarity.

Innodem Neurosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ViewMind Inc.
85%
NeuraLight
84%
Saccadous, Inc.
84%

Innodem Neurosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 19, 2021
SeedFeb 19, 2019

Key People

Founding team and executive leadership

Yves Desgagne

Chief Technology Officer

Executive Team

Innodem Neurosciences Investors

Notable investors and investment history

Innodem Neurosciences investors
InvestorRounds
Morningside GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 2, 2025

    Monthly visitors grew 167% MoM, reaching 883.

  • Nov 9, 2024

    Monthly visitors grew 117% MoM, reaching 1.5K.

Innodem Neurosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Innodem Neurosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Innodem Neurosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersMontreal
Employee Range13
Year Founded2016
Last FundingJan 19, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.